Gsk Share Discussion Threads

[cumnor] 30/3/2023 09:05

The issue here is GSK is perceived as being a weakly managed company despite it being a global leader in many areas, particularly vaccines and, of late more good news, esp on the pipeline, incl oncology front.
Big pharma is constantly inundated with threats and lawsuits-ffs Pfizer on the Covid vaccine issue which is potentially limitless yet mgmt and their lawyers brush them aside effortlessly and their share prices reflect this. GSK's CEO and senior mgmt team do not carry the same clout and conviction among the investment hierarchy.

[hjs] 29/3/2023 08:47

Trader, good news but share price will not move as the market is only interested in the court case! Which is holding up the share price moving north.

[rikky72] 27/3/2023 17:33

I think I'll go on that board and say the same thing about GSK just for balance :/

[blackhorse23] 27/3/2023 15:25

888 looks good value buy

[geckotheglorious] 24/3/2023 11:52

GSK stock falls after California court ruling on Zantac; company disagrees with decision
GSK (NYSE:GSK) said it disagrees with a California state court ruling in respect to the Goetz case related to the company's heartburn drug Zantac (ranitidine).

The British pharma giant said that after 13 epidemiological studies conducted looking at human data related to the use of ranitidine, the scientific consensus was that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.

GSK noted that the lawsuit is still at an early stage and the decision relates only to the question of whether the plaintiff's experts can testify at trial in the Goetz case.

The company added that it does not mean that the court agrees with plaintiff’s experts' scientific conclusions.

GSK would press additional defenses and the plaintiff needs to prove his case at trial, according to the company.

GSK said that the ruling does not affect other state cases or the Daubert ruling in the federal Multi-District Litigation (MDL) in December 2022.

In December 2022, Sanofi (SNY) and Pfizer (PFE) had reached an agreement in a Zantac case in California that was set to go to trial, while GSK remained a defendant in the case.

Last year, a federal judge in Florida ruled that GSK and Sanofi (SNY) would not have to face thousands of lawsuits related to claims that Zantac allegedly cause cancer. GSK had noted that the court dismissed all MDL cases alleging the five remaining cancers in the MDL.

Zantac lawsuits have been a cause of concern for not only GSK, Sanofi, and GSK consumer spinoff Haleon (HLN), but also Pfizer (PFE), Teva Pharmaceutical (TEVA), Perrigo (PRGO), Dr. Reddy's Laboratories (RDY), and Boehringer Ingelheim.

Earlier in March 2023, Rep. Rosa DeLauro asked FDA Commissioner Robert Califf how the agency would hold GSK responsible for allegedly hiding cancer risks associated with its heartburn medication Zantac. According to a report in February, GSK's (GSK) own research indicated a year before approval in 1983 that Zantac could form the carcinogen NDMA under certain circumstances.

In August 2022, the companies overall shed millions of dollars in market value on concerns over Zantac litigation.
GSK -4.06% ;to $33.79 premarket March 24

[rikky72] 24/3/2023 11:21

I think it will be in GSK's interest to squash them as soon as possible, and I believe that's what they will do. They are clearly brooking no nonsense with this, calling it 'litigation driven science'.

[tradermichael] 24/3/2023 11:11

There will be a series of >50p dips every time a 'significant' piece of litigation news emerges. In between the price will slowly creep up to return to the mid 1400s or so.
Eventually, there will be a positive result for GSK and there will be a massive leap up to 1700p.

[spoole5] 24/3/2023 10:58

These cases will go on for years

[martinthebrave] 24/3/2023 10:36

Issued: 24 March 2023, London UK

Statement: Zantac (ranitidine) litigation

In response to yesterday's Sargon ruling by the California state court in respect of the Goetz case, GSK plc (LSE/NYSE: GSK) today issued the following statement:

GSK respectfully disagrees with this ruling by the California state court. Following the 13 epidemiological studies conducted looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.

The litigation is still at an early stage and yesterday's decision relates only to the question of whether the plaintiff's experts can testify at trial in the Goetz case. It does not mean that the Court agrees with plaintiff's experts' scientific conclusions or their litigation-driven science. GSK will press additional defences and the plaintiff still needs to prove his case at trial.

This ruling does not affect other state cases or the December 2022 Daubert ruling made in the federal Multi-District Litigation.

[jonjoneil] 24/3/2023 10:31

RNS on company website re Zantac

[porsche1945] 24/3/2023 10:25

This has been trying to get down to about 12 quid for some time, think it may well be on the way this time. Anything listed on U.K. indexes is doomed, even the 5 companies propping it all up are staring to roll over ( except for Astra ) How the fxck is this shxtty ceo is still there?

[mj19] 24/3/2023 09:45

Do you ever see it go up this much

[alibizzle] 24/3/2023 09:29

This sums up gsk

[spoole5] 24/3/2023 09:24

Has Emma announced her intention to stay for another 5 years?

[spyder] 24/3/2023 09:12

Something has certainly spooked the market.

[mj19] 24/3/2023 08:34

No real reason!!

[mj19] 24/3/2023 08:25

With no news big drop for real reason

[spoole5] 24/3/2023 08:16

A battering this morning

[alibizzle] 23/3/2023 12:16

Yeah , I think early to mid summer the price going to change significantly with RSV news and court case result

[tradermichael] 23/3/2023 10:46

Well you could pretty much forecast any price across the range 1350 to 1700. What would help is a projection of time frame, I think .....;0)